Med­i­cal re­search for good rea­son is in­ves­ti­gat­ing why the im­mune sys­tem some­times goes dor­mant while on other oc­ca­sions it car­ries out rogue at­tacks on healthy cells and tis­sue.

The sys­tem that fights in­fec­tions and other health threats in­ex­pli­ca­bly can mount au­to­im­mune at­tacks re­sult­ing in many dis­eases in­clud­ing Type 1 di­a­be­tes, lu­pus and mul­ti­ple scle­ro­sis. On the con­trary, the im­mune sys­tem also can be­come in­ac­tive against can­cer.

Why it stops do­ing what it should do, and does what it shouldn’t, rep­resents one of the big­gest puz­zles in med­i­cine. And solv­ing those puz­zles is what UPMC and the Univer­sity of Pitts­burgh hope to ac­com­plish at the newly an­nounced UPMC Im­mune Trans­plant and Ther­apy Center in Bloom­field.

UPMC’s com­mit­ment of $200 mil­lion will al­low re­search­ers to take broad-based ap­proaches to un­der­stand­ing the com­plex­i­ties of dis­eases and bet­ter iden­tify drug tar­gets. And one key goal is un­der­stand­ing ex­actly how can­cer pro­tects it­self against an im­mune re­sponse.

Advertise with us

En­vi­ron­men­tal pro­tec­tion

Find­ing out how the tu­mor blocks the im­mune sys­tem could lead to ways to re­gen­er­ate the im­mune re­sponse against ma­lig­nan­cies.

The im­mune sys­tem in­cludes den­dritic cells, which reg­u­late what or­gan­isms the im­mune sys­tem de­stroys, with T cells and B cells gen­er­ally serv­ing as the sol­diers that kill bac­te­ria, vi­ruses, fungi and other agents that pose health threats.

“The tu­mor mi­cro-en­vi­ron­ment is a com­plex or­ga­ni­za­tion of many cell types, all of which have dif­fer­ent func­tions,” said Dario A. Vig­nali, leader of the Cancer Im­mu­nol­ogy Pro­gram at the UPMC Hill­man Cancer Center and vice-chair of the Univer­sity of Pitts­burgh School of Med­i­cine’s Depart­ment of Im­mu­nol­ogy.

“Some are try­ing to get rid of the tu­mor, and oth­ers are sup­port­ing the tu­mor. They are of­ten work­ing against each other. It’s a com­plex­ity that our re­search is try­ing to un­ravel to iden­tify new ther­a­peu­tic tar­gets. We are try­ing to ma­nip­u­late the tu­mor en­vi­ron­ment and im­prove the im­mune re­sponse to the tu­mor,” he said.

Advertise with us

The phar­ma­ceu­ti­cal in­dus­try tends to fo­cus on the quar­ter­back, or one key tar­get, “but we don’t even know what the field looks like or what yard line they’re on, so our ap­proach is ho­lis­tic to un­der­stand what the en­tire field looks like,” he said.

Ad­ding to the com­plex­ity is the fact that each can­cer is dif­fer­ent. Even the same can­cer type var­ies by pa­tient, ex­plain­ing why there are dif­fer­ent re­sponses to treat­ments. New im­mu­no­log­i­cal can­cer ther­a­pies have shown suc­cess, but their life-sav­ing ben­e­fits only ex­tend to 20 per­cent to 40 per­cent of pa­tients, re­search has shown.

Greg M. Del­goffe, an as­sis­tant pro­fes­sor of im­mu­nol­ogy at Pitt with his own re­search team and lab­o­ra­tory, said tu­mors not only de­tect the pres­ence of T cells but also can turn them off by re­mov­ing their fuel or nu­tri­ent source, leav­ing them in states of ex­haus­tion. In that sense, the bat­tle be­comes “a war of at­tri­tion” that the can­cer usu­ally wins with­out suc­cess­ful treat­ments.

“Our stud­ies sug­gest that the met­a­bolic makeup of the tu­mor mi­cro-en­vi­ron­ment has crit­i­cal in­flu­ence on the im­mune re­sponse to can­cer,” the Del­goffe web­site states.

Key is un­der­stand­ing the en­tire sys­tem tu­mors use to pro­tect them­selves, rather than fo­cus on each in­di­vid­ual par­tic­i­pant.

Advertise with us

“There are now far more re­sources to look at many tar­gets within the tu­mor en­vi­ron­ment more broadly and ex­pan­sively than we were able to do pre­vi­ously, and we hope that this will be truly game-chang­ing,” said Mr. Vig­nali, who holds a doctorate in im­mu­nol­ogy and in­fec­tious dis­eases.

Re­vers­ing au­to­im­mu­nity

Sim­i­larly, Mark J. Shlomchik, chair of Pitt School of Med­i­cine’s Depart­ment of Im­mu­nol­ogy, and his team is work­ing on un­der­stand­ing what prompts au­to­im­mune at­tacks against one’s own cells, with den­dritic cells as the cur­rent fo­cus of his work.

Fu­ture treat­ments could in­volve de­struc­tion of den­dritic cells that en­ter or­gans where they ini­ti­ate flare ups in lu­pus and mul­ti­ple scle­ro­sis — and po­ten­tially in other au­to­im­mune dis­eases.

“I like to ex­tract themes across many dis­eases,” he said. “If it is hap­pen­ing in one dis­ease, then it could be sim­i­lar to what’s hap­pen­ing in oth­ers.”

Advertise with us

Fol­low­ing an­other line of re­search, Dr. Shlomchik also is work­ing to clone T cells in large num­bers to re­in­tro­duce them to the pa­tient to kill can­cer.

As it turns out, each im­mune cell is dif­fer­ent, much like the hu­man fin­ger­print or snow­flake. Those dif­fer­ences al­low cells to at­tack such a wide va­ri­ety of in­fec­tions or for­eign agents, all of which also are vastly dif­fer­ent. For ex­am­ple, he said, many dif­fer­ent T-cell vari­a­tions are nec­es­sary to fight in­flu­enza, given the mul­ti­ple vari­a­tions of the vi­rus.

By cap­tur­ing the unique part of DNA in each T cell, “the cells can be cloned, im­mor­tal­ized and ex­panded,” Dr. Shlomchik said. Their re­in­tro­duc­tion in high vol­umes could over­whelm the tu­mor’s de­fense mech­a­nism and lead to tu­mor de­struc­tion.

“One of the spec­tac­u­lar things about the hu­man im­mune sys­tem is its in­cred­i­ble di­ver­sity of T cells and B cells with their unique re­cep­tors, each per­son lit­er­ally has bil­lions of re­cep­tors,” Dr. Mark Shlomchik said.

Other key part­ners in Pitt/​UPMC im­mu­nol­ogy re­search are Robert Fer­ris, di­rec­tor of the UPMC Hill­man Cancer Center, and War­ren Shlomchik, di­rec­tor of Hemato­poi­etic Stem Cell Trans­plant and Cell Ther­apy at UPMC and Mark Shlomchik’s brother.

Advertise with us

Over­all, Dr. Mark Shlomchik said that Mr. Vig­nali — “one of the world lead­ers in un­der­stand­ing the tu­mor mi­cro-en­vi­ron­ment” — along with other teams at the cen­ter will be work­ing to solve dif­fer­ent parts of the same com­plex ques­tion: “How T cells at­tack tu­mors.”

David Templeton: dtempleton@post-gazette.com or 412-263-1578. Twitter: @templetoons. The Delgoffe website is available at  http://www.delgoffe-lab.com.